Company intelligence / Profile preview
Remedor Biomed
Israelremedor.com ↗
- Ownership
- Private
- Employees
- ~6
- Development stage
- Other
01
Overview
WOUNDAGEL™, a topical hydrogel embedding biologic agents, has demonstrated the ability to accelerate diabetic foot ulcer healing up to four times faster than standard of care. The product has shown safety and efficacy in preclinical studies and is currently being evaluated in advanced phase II clinical trials for hard-to-heal diabetic ulcers. The company’s technology leverages the synergistic effect of erythropoietin and fibronectin to promote wound healing and connective tissue reconstruction. No commercial or late-stage results are yet available.
- Therapeutic areas
- EndocrinologyDermatology
- Modalities
- ProteinRecombinant proteinHydrogel-based drug delivery therapyBiologic
- Industry
- Biotech
02
Drug pipeline
1 assetBeyond the preview
Go deeper on Remedor Biomed.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Remedor Biomed.